Drug firm Lupin Ltd today said its Pithampur unit 2 manufacturing facility located in Indore has been cleared by Health Canada after a review.
"Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'," Lupin said in a BSE filing.
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
Shares of Lupin were trading 2.32 per cent higher at Rs 753.45 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
